MOLN PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

MOLN ▼ -3.30% at T+5d

NEUTRAL call ✗ call lost -3.30% · α vs SPY -5.65% · entry $4.24 → $4.10

Next anchor: T+20d in 10d

Currently $4.18 · -1.42% from $4.24 entry

Entry anchored
May 1, 2026
via day open

T+1d

+3.94%

call +3.94% · α +4.28%

$4.41

settled 18d ago

T+5d

-3.30%

call -3.30% · α -5.65%

$4.10

settled 14d ago

T+20d

—

call — · α —

—

in 10d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Molecular Partners announced publication of Phase 1 data for MP0317, a tumor-localized CD40 agonist, in Nature Cancer. The data show a favorable safety profile and proof-of-mechanism, but clinical activity was modest with one partial response among 46 patients. An investigator-initiated Phase 2 trial in cholangiocarcinoma is enrolling.

Actionable Insight

Phase 1 data are positive but early; the modest response rate limits immediate stock catalyst. Monitor for Phase 2 top-line results in cholangiocarcinoma (expected in 2027). No change to fundamental outlook.

Key Facts

Phase 1 data published in Nature Cancer show MP0317 activates CD40 locally in tumors with favorable safety.
One unconfirmed partial response and 14 stable disease observed in 46 patients with advanced solid tumors.
Phase 2 investigator-initiated trial in front-line cholangiocarcinoma open with patient dosing ongoing.
Pharmacokinetics support weekly or every-three-week dosing; combination with checkpoint inhibitors is being explored.

Financial Impact

No financial data disclosed; early-stage clinical program with no near-term revenue impact.

Risk Factors

Phase 2 trial may fail to show improved progression-free survival.
Competition from other CD40 agonists and immune therapies.
Company has no approved products and relies on financing for operations.

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

80% bullish (10 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3285827

4 reports for MOLN

T+1T+5T+20T+60

Filters

Reports for MOLN — sortable, filterable
	Type				Now
May 12, 2026 9d ago	6-K NEUTRAL ★ 5/10	$4.00 $3.74	▼ −6.50%	▼ −5.34%	$4.18 (+4.50%)
May 1, 2026 21d ago	Press Release NEUTRAL ★ 4/10	$4.24 $4.10	▼ −3.30%	▼ −5.65%	$4.18 (−1.42%)
Mar 30, 2026 7w ago	6-K NEUTRAL ★ 3/10	$3.93 $3.87	▼ −1.53%	▼ −5.83%	$4.18 (+6.36%)
Mar 12, 2026 10w ago	Press Release MIXED ★ 6/10	$4.22 $4.59	▲ +8.65%	▲ +10.77%	$4.18 (−0.95%)

US Market Status

Market Open — Closes in 4h 15m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access